Active Cancer Brain & Nervous System

Nanoparticle-Assisted liquid biopsy based on Extracellular for Early Diagnosis of Glioblastoma

Summary

Original abstract (not yet simplified)

Glioblastoma (GB) is the deadliest primary malignant brain tumour, with a median survival of less than one year while current diagnostic methods suffer from significant limitations, leading to misdiagnosis and poor progression monitoring and are accompanied by invasive biopsy. Currently, there are no blood-based biomarkers available as support tool for GB management. A promising approach for such systems are liquid...

View original technical description
Glioblastoma (GB) is the deadliest primary malignant brain tumour, with a median survival of less than one year while current diagnostic methods suffer from significant limitations, leading to misdiagnosis and poor progression monitoring and are accompanied by invasive biopsy. Currently, there are no blood-based biomarkers available as support tool for GB management. A promising approach for such systems are liquid biopsies based on Extracellular Vesicles (EVs) that present a promising and minimally invasive approach. EVs act as versatile communication hubs, transporting a meticulously selected cargos that include various RNA molecules. The specific composition of EVs is influenced by their cell of origin, highlighting their potential as specific biomarkers for aggressive tumours such as GB. The NExGliO project aims for the development of multiplex biosensors for simultaneous detection on array of EVs-based ncRNAs signature specialized for GB diagnosis. This will be achieved via noble metal NPs which are frequently utilized as SERS substrates due to their strong plasmonic properties for ncRNAs detection. Supporting AI technologies will be developed to improve early-stage cancer diagnosis through ncRNA signature identifying algorithms. The NExGliO Staff Exchange brings together internationally recognised experts with complementary expertise from molecular biology, chemistry, nanotechnology, and AI to develop a robust platform for the early diagnosis and monitoring of GB, thus reducing reliance on invasive procedures and improving survival rates. The secondments and local training will synergize expertise from both academic and non-academic partners for a robust collaboration and to generate knowledge transfer between the consortium partners.The direct application of this knowledge, will enhance the potential to introduce innovative products to the market and solidify their position in the relevant sector as well as benefit the careers of the involved personnel.

Related Research

Grants with similar aims, by meaning.

Nanoplatforms and Oncolytic viruses for novel cancer immunotherapy strategies
Market Feasibility for a Engineering Biology Approach to Cell Therapy for Brain Cancer and Regenerative Medicine
EDIFICE - Early Detection of cancer recurrence In patients with glioblastoma using artiFicial IntelligenCE through imaging
Nanotechnology-enabled multi-omic liquid biopsies in non-small cell lung cancer
Porous 3D Silica Nanoparticle Assemblies as Post-surgical Drug Delivery Implants to Reduce Glioblastoma Recurrence

Original classification

HORIZON

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.